13F Holdings
中文EN

ENGN enGene Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1980845 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.6%
TTM EPS YoY305.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-60.5%
ROA-48.8%
ROIC (approx.)-60.4%
Asset turnover—

Leverage & solvency

Liabilities / assets20.1%
Debt / equity0.00x
Current ratio10.21x
Interest coverage-44.51x

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-10-31FY20242024-10-31FY20232023-10-31FY20222022-10-31
Income statement
Revenue————
R&D expense$94.48M$38.31M$16.46M$15.47M
SG&A expense$28.68M$23.98M$9.60M$3.96M
Operating income-$123.17M-$62.30M-$26.06M-$19.43M
Interest expense$2.99M$2.80M$4.95M$1.42M
Pretax income-$117.30M-$55.16M-$99.90M-$24.44M
Income tax$0-$19,000$17,000$22,000
Net income-$117.30M-$55.14M-$99.92M-$24.46M
EBITDA-$122.67M-$62.00M-$25.86M-$19.23M
EPS (basic)2.291.46151.2244.30
EPS (diluted)2.291.46151.2244.30
Dividends declared per share0.000.000.00—
Weighted avg. shares (diluted)51.12M37.78M692,609655,153
Balance sheet
Cash & equivalents$50.15M$173.00M$81.52M$20.43M
Short-term investments$143.58M$65.33M——
Current assets$201.39M$247.36M$85.44M$22.58M
PP&E, net$2.48M$1.17M$589,000$387,000
Total assets$221.47M$311.17M$86.96M$23.91M
Current liabilities$31.98M$14.66M$5.26M$5.10M
Total liabilities$53.76M$38.56M$14.47M$47.41M
Shareholders' equity$167.71M$272.61M$72.49M-$76.61M
Shares outstanding52.02M50.98M23.20M665,767
Cash flow statement
Operating cash flow-$99.24M-$48.28M-$24.74M-$17.59M
Capital expenditure$1.49M$925,000$318,000$153,000
Free cash flow-$100.72M-$49.21M-$25.06M-$17.75M
Investing cash flow-$25.14M-$125.95M-$318,000-$153,000
Financing cash flow$1.52M$265.72M$86.15M$27.97M
Depreciation & amortization$500,000$300,000$200,000$200,000
Stock-based compensation$9.65M$5.32M$3.45M$116,000
Dividends paid——$0—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.